Article citationsMore>>
Guimbaud, R., Louvet, C., Ries, P., Ychou, M., Maillard, E., André, T., et al. (2014) Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French Intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) Study. Journal of Clinical Oncology, 32, 3520-3526.
http://dx.doi.org/10.1200/JCO.2013.54.1011
has been cited by the following article:
-
TITLE:
Trastuzumab Re-Introduction with FOLFIRI for Treatment of HER2 Overexpression-Advanced Gastric Adenocarcinoma Following Failure of Other Trastuzumab-Based Chemotherapy Regimens
AUTHORS:
Olivier Dubreuil, Aziz Zaanan, Olivier Pellerin, Jean-Baptiste Bachet, Philippe Rougier, Julien Taieb
KEYWORDS:
Stomach Neoplasm, Trastuzumab, Treatment Reintroduction
JOURNAL NAME:
Case Reports in Clinical Medicine,
Vol.4 No.4,
April
17,
2015
ABSTRACT:
A 67-year-old man diagnosed with HER2 overexpression advanced gastric adenocarcinoma and metastasis to liver and lungs was admitted for tertiary care. He received a third line chemotherapy that consists of trastuzumab combined with FOLFIRI regimen (irinotecan plus 5-FU/LV) following a disease relapse after an initial successful response to a combination of 5FU + oxaliplatin and trastuzumab. The patient showed a favorable and prolonged response to it. In addition the chemotherapy was well tolerated and devoid of remarkable side effects. The response to trastuzumab + FOLFIRI was assessed clinically and through CT scan imaging and upper gastrointestinal endoscopy. This case report shows that firstly the combination of FOLFIRI and trastuzumab could be tested as another regimen in metastatic gastric cancer, and, secondly, that in this disease, like in metastatic breast cancer, the continuation of trastuzumab after an initial progression under this antibody could be tested in order to improve the efficacy of the treatment Trastuzumab re-introduction with FOLFIRI for treatment of HER2 overexpression-advanced gastric adenocarcinoma following failure of other trastuzumab-based chemotherapy regimens.
Related Articles:
-
H. Abbas, Shimaa Ahmed, Ahmed A. S. Salem, Mohamed Abou Elmagd Salem, Mahmoud Hussin, Wessam A. El Sherief
-
Tetsu Yamamoto, Ryoji Hyakudomi, Shinichi Sugimoto, Atsuo Tokuka, Yoshitoshi Sato, Satoshi Nagai, Hikota Hayashi, Masahikoo Igarashi, Kenji Takubo, Yoshitsugu Tajima
-
Abdulgafoor Kassim, Saeed Thabet, Sadik Al-Fakih, Mohammed Alqobaty, Ramea Alathwary, Sana Ameen
-
Ofer Purim, Yulia Kundel, Roni Shapira, Baruch Brenner
-
Anna Maria Cardinale, Nadia Parodi